Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran
Oct 2026· Journal of Diabetes and Metabolic Disorders· Vol 25· 0 citations· 34 references
Medicine
TL;DR
Although tirzepatide provided greater health benefits, its higher cost limited its cost-effectiveness at current prices, and semaglutide was the cost-effective injectable GLP-1-1-based therapy in Iran.
In this indirect treatment comparison for obesity treatment in adults without T2D, with obesity, or overweight with ≥1 ORC, compared with semaglutide, tirzepatide 10 or 15’mg was associated with improvements in weight reduction, body composition and several cardiometabolic risk factors and generally similar safety prof...
A. Ciudin, Erin Johansson, S. Zimner-Rapuch et al.· International Journal of Obe...· 0 citations
INTRODUCTION.
In the last two decades, pharmacotherapy for obesity and type 2 diabetes mellitus has evolved toward drugs that target the incretin system, such as semaglutide, a glucagon-like peptide-1 (GLP-1) receptoragonist, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 recept...
E. M. Eliseeva, A. A. Druzhinina, A. A. Chistokhina· Safety and Risk of Pharmacot...· 0 citations
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in obesity and type 2 diabetes mellitus (T2DM), but comparative real-world evidence from the Middle East remains limited. We compared the effectiveness, documented adverse events, adherence and persistence of once-weekly semaglutide and o...
Najwa Al Himali, Hanan Al Habsi, Ahmed Almushrafi et al.· Journal of Clinical Medicine· 0 citations
Introduction: Semaglutide has shown substantial weight reduction in trials, but real-world evidence from South Asian populations is scarce. We evaluated the efficacy and safety of once-weekly semaglutide 2·4 mg over 26 weeks in adults with overweight or obesity, with and without type 2 diabetes mellitus (T2DM).
Methods...
Q. T. Islam· Journal of Association of Cl...· 0 citations
Liraglutide and semaglutide demonstrate significant superiority over placebo in reducing body weight and body mass index in obese children and adolescents and substantiate therapy in pediatric practice with careful assessment of the benefit-risk ratio.
E. A. Kovaleva, O. Nemyatykh, S. Okovity et al.· Medical Technologies. Assess...· 0 citations
INTRODUCTION
Tirzepatide has demonstrated good efficacy and safety in the management of type 2 diabetes (T2D) in clinical trials. As the importance of early intensive intervention is known, the tirzepatide benefit for early glycemic and weight management (T-BEAT) study investigated the real-world effectiveness of tirze...
Hironori Waki, H. Kagitani, S. Osaga et al.· Diabetes Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
